科普蒂辛通过准线粒体复合体I的作用,在三阴性乳腺癌中发挥抗瘤作用
Yunfu Shen1, You Yang2, Zi Wang1
1State Key Laboratory of Quality Research in Chinese Medicine, Macau University of Science and Technology, Macau, China.
British journal of pharmacology
|July 10, 2024
概括
科普蒂辛有效地向线粒体复合体I,这是三阴性乳腺癌 (TNBC) 的关键漏洞. 这种新的治疗方法在抑制TNBC增殖方面显著有前途,为患者提供了新的希望.
科学领域:
- 生物化学 生物化学
- 癌症生物学 癌症生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 三重阴性乳腺癌 (TNBC) 由于治疗选择有限和预后不佳, presents一个重要的临床挑战.
- 新出现的证据凸显了TNBC对线粒体氧化酸化的依赖,以生产能量.
- 针对代谢脆弱性为TNBC提供了一个有前途的治疗策略.
研究的目的:
- 作为TNBC的潜在治疗剂,研究线粒体电子运输链 (ETC) 复合物I的新型抑制剂coptisine,作为TNBC的潜在治疗剂.
- 阐明科普蒂辛诱导线粒体功能障碍并抑制TNBC生长的分子机制.
- 在TNBC的临床前模型中评估康普蒂辛的疗效.
主要方法:
- 在TNBC中对线粒体代谢的生物信息分析.
- 使用TNBC细胞系进行体外研究,以评估丁对线粒体功能,细胞代谢,细胞亡和增殖的影响.
- 使用TNBC异种移植小鼠模型进行体内研究,以评估coptisine的治疗疗效和作用机制.
主要成果:
- 线粒体ETC复合体I被确定为TNBC中的关键代谢脆弱性.
- 科普蒂辛对ETC复合物I具有特定的抑制活性.
- 科普蒂辛治疗显著损害了线粒体功能,改变了细胞代谢,诱导了细胞亡,并抑制了TNBC细胞增殖.
- 在体内,科普蒂辛的使用导致了以一种依赖于功能ETC复合体I的方式大幅抑制瘤生长.
结论:
- 科普蒂辛作为线粒体ETC复合体I的强有力的抑制剂.
- 针对ETC复合物I的代谢脆弱性,用哥普提辛向TNBC显示出显著的治疗潜力.
- 这些发现支持进一步发展丁作为三阴性乳腺癌的新型治疗策略.
更多相关视频
10:39Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module
Published on: June 18, 2015
13.1K
19:44Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
Published on: May 30, 2012
18.7K
相关概念视频
01:46Electron Transport Chain: Complex I and II
12.8K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
12.8K
01:15Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
01:10Drugs that Destabilize Microtubules
2.0K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
2.0K
02:34Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K